33 withdrawn. 33 Phase 2, 9 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 33 | Withdrawn 33 |
| Phase 1 | 9 | Withdrawn 9 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Heart Failure: new trials by email Literature Review of Heart Failure trials Research Report on Heart Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCs in Recently Diagnosed Non-ischemic Heart Failure Allogeneic adipose tissue-derived mesenchymal stem cells, Cryostor CS10 - Non-Ischemic Heart Failure, Reduced Ejection Fraction Heart Failure | Phase 2 | Withdrawn | Cell to Cure ApS | 2026-03-01 | 2026-04-01 | |
| Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension JK07 - HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Salubris Biotherapeutics Inc | 2025-12-15 | 2026-05-15 | |
| A Proof-of-concept Trial for OPC 131461 in Patients Hospitalized for Worsening Heart Failure OPC-131461, Placebo - Heart Failure | Phase 2 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2025-04-30 | 2026-04-17 | |
| Immediate Release Torsemide Versus Extended Release Torsemide After Salty Meal Immediate release torsemide 20mg tablet, Extended release torsemide 24mg tablet - Heart Failure | Phase 2 | Withdrawn | Sarfez Pharmaceuticals, Inc. | 2024-11-15 | 2026-04-27 | |
| Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy CDR132L, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Cardior Pharmaceuticals GmbH | 2024-04-30 | 2026-07-07 | |
| SGLT2-Inhibitors for Sleep Apnea in Heart Failure Dapagliflozin, WatchPat - Heart Failure, Sleep Disordered Breathing | Phase 2 | Withdrawn | Columbia University | 2023-12-01 | 2024-05-13 | |
| Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure Furosemide Pill 150% equivalent iv dose, Furosemide Pill 200% equivalent iv dose, Furosemide Injection - Heart Failure | Phase 2 / Phase 3 | Withdrawn | Jan Kochanowski University | 2022-12-07 | 2025-02-20 | |
| Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List Dapagliflozin 10mg, Placebo - End-stage Heart Failure | Phase 2 | Withdrawn | Hospices Civils de Lyon | 2022-09-01 | 2023-08-07 | |
| Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES Sulforaphane - Diastolic Dysfunction, Systolic Dysfunction | Phase 1 / Phase 2 | Withdrawn | Texas Tech University Health Sciences Center | 2022-07-01 | 2026-06-29 | |
| The Effect of Inflammation in Heart Failure Dapagliflozin, MRI scan, CMR imaging - Myocardial Dysfunction, Heart Failure | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2022-06-23 | 2022-06-27 | |
| Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction IMR-687, IMR-687 Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Cardurion Pharmaceuticals, Inc. | 2022-04-01 | 2025-05-15 | |
| RIGENERA 2.0 Trial rhu G-CSF, optimal standard of care, Myocardial Contrast Echocardiography - Anterior Myocardial Infarction, Heart Failure | Phase 2 | Withdrawn | Catholic University of the Sacred Heart | 2020-01-01 | 2022-03-29 | |
| Accessing Mobility Using Wearable Sensors Exercise - COPD, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Baylor College of Medicine | 2018-05-21 | 2025-08-27 | |
| Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure sacubitril+valsartan, valsartan - Heart Failure | Phase 2 | Withdrawn | Hannover Medical School | 2017-12-14 | 2018-10-09 | |
| Ruboxistaurin in New York Heart Failure Classification III-IV Patients Ruboxistaurin - Heart Failure | Phase 1 / Phase 2 | Withdrawn | University of Tennessee | 2017-06-28 | 2022-06-06 | |
| Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease Anakinra - Heart Failure, Systolic, Renal Disease, End Stage | Phase 2 | Withdrawn | Virginia Commonwealth University | 2017-04-03 | 2019-05-17 | |
| Dobutamaine Versus Milrinone in Cardiorenal Syndrome Milrinone, Dobutamine - Cardiorenal Syndrome | Phase 2 | Withdrawn | Maimonides Medical Center | 2016-03-01 | 2018-08-10 | |
| Telehealth Self Management for CHF Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF - Heart Failure | Phase 1 / Phase 2 | Withdrawn | US Department of Veterans Affairs | 2014-11-01 | 2014-12-02 | |
| A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies JNJ-54452840, Placebo - Heart Failure | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2014-11-01 | 2014-04-09 | |
| Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure D-ribose, Placebo - Congestive Heart Failure | Phase 2 | Withdrawn | RiboCor, Inc. | 2013-07-01 | 2016-07-14 |
Showing 20 of 33. Sign in to see all of them.
Cardiovascular Diseases (4) · Heart Failure, Diastolic (3) · Heart Failure, Systolic (3) · Cardio-Renal Syndrome (2) · Anterior Wall Myocardial Infarction (1) · Cardiomegaly (1) · Cardiomyopathies (1) · Cardiomyopathy, Dilated (1) · Communication (1) · Coronary Disease (1) · Death, Sudden, Cardiac (1) · Fibromatosis, Gingival, 2 (1) · Heart Diseases (1) · Hypertension, Pulmonary (1)
Heart Diseases (32) · Cardiovascular Diseases (29) · Pathological Conditions, Signs and Symptoms (9) · Pathologic Processes (7) · Respiratory Tract Diseases (4) · Vascular Diseases (4) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Kidney Diseases (3) · Male Urogenital Diseases (3) · Renal Insufficiency (3) · Urogenital Diseases (3) · Urologic Diseases (3) · Chronic Disease (2)
dapagliflozin (3) · Dobutamine (2) · Albuterol (1) · Allopurinol (1) · Angiotensin Receptor Antagonists (1) · Carvedilol (1) · Educational Status (1) · Exercise (1) · Furosemide (1) · Interleukin 1 Receptor Antagonist Protein (1) · Istaroxime (1) · Ivabradine (1) · JNJ-54452840 (1) · Magnetic Resonance Imaging (1) · Melatonin (1)
Baylor College of Medicine (1) · Brigham and Women's Hospital (1) · Cardior Pharmaceuticals GmbH (1) · Cardurion Pharmaceuticals, Inc. (1) · Catholic University of the Sacred Heart (1) · Cell to Cure ApS (1) · Columbia University (1) · Cytokinetics (1) · Debiopharm International SA (1) · Duke University (1) · Hannover Medical School (1) · Hospices Civils de Lyon (1) · Imperial College London (1) · Jan Kochanowski University (1) · Janssen Research & Development, LLC (1)
United States (16) · Canada (2) · Germany (2) · Denmark (1) · France (1) · Ireland (1) · Italy (1) · Poland (1) · United Kingdom (1)
Abbas A Qayyum, MD MSc PhD (1) · Antonio Maria Leone, MD, PhD (1) · Aslan T Turer, MD, MHS (1) · Astrid Hummel, MD (1) · Benjamin W Van Tassell, PharmD (1) · Bijan Najafi, PhD (1) · Charlene A Pope, PhD MPH BSN (1) · Christopher B Granger, MD (1) · Daniel Beug, MD (1) · Dermot J McCaffrey, MB MRCPI FRACP (1) · Douglas W. Losordo, M.D. (1) · Eric WF Alton (1) · Filippo Crea, MD (1)
2025 (1), K23HL071562 (1)